SG11202111003UA - Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate - Google Patents

Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate

Info

Publication number
SG11202111003UA
SG11202111003UA SG11202111003UA SG11202111003UA SG11202111003UA SG 11202111003U A SG11202111003U A SG 11202111003UA SG 11202111003U A SG11202111003U A SG 11202111003UA SG 11202111003U A SG11202111003U A SG 11202111003UA SG 11202111003U A SG11202111003U A SG 11202111003UA
Authority
SG
Singapore
Prior art keywords
cancer
compound
fumarate salt
crystal form
fumaric acid
Prior art date
Application number
SG11202111003UA
Other languages
English (en)
Inventor
Sze-Wan Li
Mark Robert Bray
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of SG11202111003UA publication Critical patent/SG11202111003UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202111003UA 2019-04-24 2020-04-23 Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate SG11202111003UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837858P 2019-04-24 2019-04-24
PCT/CA2020/050535 WO2020215155A1 (en) 2019-04-24 2020-04-23 Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate

Publications (1)

Publication Number Publication Date
SG11202111003UA true SG11202111003UA (en) 2021-11-29

Family

ID=72940551

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111003UA SG11202111003UA (en) 2019-04-24 2020-04-23 Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate

Country Status (16)

Country Link
US (1) US12325700B2 (https=)
EP (1) EP3959209A4 (https=)
JP (1) JP7705351B2 (https=)
KR (1) KR20220004102A (https=)
CN (1) CN113966330B (https=)
AU (1) AU2020264143A1 (https=)
BR (1) BR112021021106A2 (https=)
CA (1) CA3137191A1 (https=)
EA (1) EA202192903A1 (https=)
IL (1) IL287394A (https=)
MA (1) MA55767A (https=)
MX (1) MX2021012993A (https=)
SA (1) SA521430647B1 (https=)
SG (1) SG11202111003UA (https=)
TW (1) TWI862582B (https=)
WO (1) WO2020215155A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7717842B2 (ja) 2021-05-11 2025-08-04 オリック ファーマシューティカルズ,インク. ポロ様キナーゼ4阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
EP2205241B1 (en) 2007-09-25 2014-05-21 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
US8586598B2 (en) 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
ES2706066T3 (es) 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
US20140051679A1 (en) 2011-10-12 2014-02-20 Univeristy Health Networks Kinase inhibitors and method of treating cancer with same
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer
HUE043194T2 (hu) * 2013-10-18 2019-08-28 Univ Health Network PLK-4 inhibitor sója és kristályformái

Also Published As

Publication number Publication date
BR112021021106A2 (pt) 2021-12-14
WO2020215155A8 (en) 2020-11-26
TW202104216A (zh) 2021-02-01
JP7705351B2 (ja) 2025-07-09
KR20220004102A (ko) 2022-01-11
TWI862582B (zh) 2024-11-21
SA521430647B1 (ar) 2024-01-27
MX2021012993A (es) 2021-12-10
MA55767A (fr) 2022-03-02
IL287394A (en) 2021-12-01
US12325700B2 (en) 2025-06-10
WO2020215155A1 (en) 2020-10-29
EP3959209A4 (en) 2022-12-28
AU2020264143A1 (en) 2021-10-28
EA202192903A1 (ru) 2022-02-09
CA3137191A1 (en) 2020-10-29
EP3959209A1 (en) 2022-03-02
US20220204494A1 (en) 2022-06-30
CN113966330A (zh) 2022-01-21
JP2022530028A (ja) 2022-06-27
CN113966330B (zh) 2024-09-13

Similar Documents

Publication Publication Date Title
US11667627B2 (en) Salt and crystal forms of PLK-4 inhibitor
WO2012044595A1 (en) Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
AU2014336929A1 (en) Salt and crystal forms of PLK-4 inhibitor
US11878980B2 (en) Solid forms of TTK inhibitor
US12325700B2 (en) Crystal form S4 of the PLK4 inhibitor (1R,2S)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1 h-imidazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one fumarate
EA044843B1 (ru) Кристаллическая форма ингибитора plk4
CA3030230C (en) Solid forms of ttk inhibitor
HK1227404A1 (en) Salt and crystal forms of plk-4 inhibitor
HK1227404B (en) Salt and crystal forms of plk-4 inhibitor
HK40007702B (en) Solid forms of ttk inhibitor
HK40007702A (en) Solid forms of ttk inhibitor